{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,18]],"date-time":"2026-04-18T13:34:12Z","timestamp":1776519252377,"version":"3.51.2"},"reference-count":28,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100003018","name":"Institute for Myeloma and Bone Cancer Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100003018","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.com.au","clinicalkey.es","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Leukemia Research"],"published-print":{"date-parts":[[2025,4]]},"DOI":"10.1016\/j.leukres.2025.107677","type":"journal-article","created":{"date-parts":[[2025,2,28]],"date-time":"2025-02-28T17:06:30Z","timestamp":1740762390000},"page":"107677","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Outcomes of triple-class refractory multiple myeloma patients at a single clinic: A retrospective study"],"prefix":"10.1016","volume":"151","author":[{"given":"Ryan","family":"Danis","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sean","family":"Bujarski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Yashar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ashley","family":"Del Dosso","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-2397-8265","authenticated-orcid":false,"given":"Jonathan","family":"Moore","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-3771-6447","authenticated-orcid":false,"given":"Sarah","family":"Mettias","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1587-6104","authenticated-orcid":false,"given":"James R.","family":"Berenson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.leukres.2025.107677_bib1","article-title":"Multiple myeloma","volume":"3","author":"Kumar","year":"2017","journal-title":"Nat. Rev. Dis. Prim."},{"key":"10.1016\/j.leukres.2025.107677_bib2","article-title":"Epidemiology, staging, and management of multiple myeloma","volume":"9","author":"Padala","year":"2021","journal-title":"Med. Sci. (Basel, Switzerland)"},{"key":"10.1016\/j.leukres.2025.107677_bib3","first-page":"1915","article-title":"Trends in overall survival and costs of multiple myeloma, 2000-2014","volume":"31","author":"Fonseca","year":"2017","journal-title":"Leuk. [Internet]"},{"issue":"5","key":"10.1016\/j.leukres.2025.107677_bib4","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2007-08-104984","article-title":"Recent major improvement in long-term survival of younger patients with multiple myeloma","volume":"11","author":"Brenner","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2025.107677_bib5","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1007\/s11523-023-00990-6","article-title":"Clinical outcomes and serum B-cell maturation antigen levels in a real-world unselected population of newly diagnosed multiple myeloma patients","volume":"18","author":"Jew","year":"2023","journal-title":"Target Oncol."},{"key":"10.1016\/j.leukres.2025.107677_bib6","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1038\/s41408-022-00757-8","article-title":"Second- and third-line treatment strategies in multiple myeloma: a referral-center experience","volume":"12","author":"Goldman-Mazur","year":"2022","journal-title":"Blood Cancer J."},{"key":"10.1016\/j.leukres.2025.107677_bib7","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1038\/leu.2017.329","article-title":"Management of relapsed and refractory multiple myeloma: novel agents, antibodies, immunotherapies and beyond","volume":"32","author":"Chim","year":"2018","journal-title":"Leukemia"},{"key":"10.1016\/j.leukres.2025.107677_bib8","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1038\/s41375-022-01531-2","article-title":"LocoMMotion: a prospective, non-interventional, multinational study of real-life current standards of care in patients with relapsed and\/or refractory multiple myeloma","volume":"36","author":"Mateos","year":"2022","journal-title":"Leukemia"},{"key":"10.1016\/j.leukres.2025.107677_bib9","doi-asserted-by":"crossref","first-page":"2266","DOI":"10.1038\/s41375-019-0435-7","article-title":"Outcomes of patients with multiple myeloma refractory to CD38-targeted monoclonal antibody therapy","volume":"33","author":"Gandhi","year":"2019","journal-title":"Leukemia"},{"key":"10.1016\/j.leukres.2025.107677_bib10","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1038\/s41375-021-01433-9","article-title":"Outcomes of triple class (proteasome inhibitor, IMiDs and monoclonal antibody) refractory patients with multiple myeloma","volume":"36","author":"Zanwar","year":"2022","journal-title":"Leukemia"},{"key":"10.1016\/j.leukres.2025.107677_bib11","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1080\/10428194.2022.2140284","article-title":"Treatment patterns and overall survival of patients with double-class and triple-class refractory multiple myeloma: a US electronic health record database study","volume":"64","author":"Wang","year":"2023","journal-title":"Leuk. Lymphoma"},{"issue":"Supplement 1","key":"10.1016\/j.leukres.2025.107677_bib12","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1182\/blood-2023-189506","article-title":"Comparison of the efficacy in clinical trials versus effectiveness in the real-world of treatments for multiple myeloma: a population-based cohort study","volume":"142","author":"Visram","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2025.107677_bib13","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1111\/bjh.15504","article-title":"Efficacy of retreatment with immunomodulatory drugs and proteasome inhibitors following daratumumab monotherapy in relapsed and refractory multiple myeloma patients","volume":"183","author":"Oostvogels","year":"2018","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.leukres.2025.107677_bib14","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.clml.2022.11.008","article-title":"Treatment patterns, survival, quality of life, and healthcare resource use among patients with triple-class refractory multiple myeloma in US clinical practice: findings from the connect MM disease registry","volume":"23","author":"Lee","year":"2023","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"10.1016\/j.leukres.2025.107677_bib15","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1016\/S2352-3026(23)00217-X","article-title":"Addition of daratumumab to lenalidomide, bortezomib, and dexamethasone for transplantation-eligible patients with newly diagnosed multiple myeloma (GRIFFIN): final analysis of an open-label, randomised, phase 2 trial","volume":"10","author":"Voorhees","year":"2023","journal-title":"Artic. Lancet Haematol."},{"key":"10.1016\/j.leukres.2025.107677_bib16","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/S1470-2045(20)30756-7","article-title":"Treatment of relapsed and refractory multiple myeloma: recommendations from the International Myeloma Working Group","volume":"22","author":"Zamagni","year":"2021","journal-title":"Policy Rev. Lancet Oncol."},{"key":"10.1016\/j.leukres.2025.107677_bib17","first-page":"48","article-title":"Overall survival with oral selinexor plus low-dose dexamethasone versus real-world therapy in triple-class-refractory multiple myeloma","volume":"2","author":"Richardson","year":"2021","journal-title":"Eur. J. Haematol."},{"key":"10.1016\/j.leukres.2025.107677_bib18","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.3109\/10428194.2012.733879","article-title":"Dexamethasone, cisplatin, doxorubicin, cyclophosphamide and etoposide (DPACE) is an effective salvage regimen for multiple myeloma refractory to novel agents","volume":"54","author":"Ronchetti","year":"2012","journal-title":"Leuk. Lymphoma"},{"key":"10.1016\/j.leukres.2025.107677_bib19","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1016\/j.clml.2019.05.001","article-title":"Retrospective review of the use of high-dose cyclophosphamide, bortezomib, doxorubicin, and dexamethasone for the treatment of multiple myeloma and plasma cell leukemia","volume":"19","author":"Tabchi","year":"2019","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"10.1016\/j.leukres.2025.107677_bib20","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/2047-783X-15-1-13","article-title":"Bendamustine in patients with relapsed or refractory multiple myeloma","volume":"15","author":"Michael","year":"2010","journal-title":"Eur. J. Med. Res."},{"key":"10.1016\/j.leukres.2025.107677_bib21","doi-asserted-by":"crossref","first-page":"1630","DOI":"10.1016\/S1470-2045(20)30525-8","article-title":"Venetoclax or placebo in combination with bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma (BELLINI): a randomised, double-blind, multicentre, phase 3 trial","volume":"21","author":"Kumar","year":"2020","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.leukres.2025.107677_bib22","first-page":"14","article-title":"Efficacy and safety of venetoclax-based regimens for the treatment of relapsed\/refractory multiple myeloma: a systemic review and meta-analysis","volume":"6","author":"Xu","year":"2023","journal-title":"Ther. Adv. Hematol."},{"key":"10.1016\/j.leukres.2025.107677_bib23","doi-asserted-by":"crossref","first-page":"2087","DOI":"10.1200\/JCO.22.01365","article-title":"Idecabtagene vicleucel for relapsed\/refractory multiple myeloma: real-world experience from the myeloma CAR T consortium","volume":"41","author":"Hansen","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.leukres.2025.107677_bib24","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1038\/s41408-021-00507-2","article-title":"KarMMa-RW: Comparison of idecabtagene vicleucel with real-world outcomes in relapsed and refractory multiple myeloma","volume":"11","author":"Jagannath","year":"2021","journal-title":"Blood Cancer J."},{"key":"10.1016\/j.leukres.2025.107677_bib25","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1200\/JCO.22.00842","article-title":"Ciltacabtagene autoleucel, an anti-B-cell maturation antigen chimeric antigen receptor T-cell therapy, for relapsed\/refractory multiple myeloma: CARTITUDE-1 2-year follow-up","volume":"41","author":"Martin","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.leukres.2025.107677_bib26","doi-asserted-by":"crossref","first-page":"2232","DOI":"10.1056\/NEJMoa2204591","article-title":"Talquetamab, a T-Cell\u2013redirecting GPRC5D bispecific antibody for multiple myeloma","volume":"387","author":"Chari","year":"2022","journal-title":"N. Engl. J. Med."},{"issue":"15_suppl","key":"10.1016\/j.leukres.2025.107677_bib27","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2021.39.15_suppl.8006","article-title":"Efficacy and safety of elranatamab (PF-06863135), a B-cell maturation antigen (BCMA)-CD3 bispecific antibody, in patients with relapsed or refractory multiple myeloma (MM)","volume":"39","author":"Bahlis","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.leukres.2025.107677_bib28","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1056\/NEJMoa2203478","article-title":"Teclistamab in relapsed or refractory multiple myeloma","volume":"387","author":"Moreau","year":"2022","journal-title":"N. Engl. J. Med."}],"container-title":["Leukemia Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212625000372?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212625000372?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,3,22]],"date-time":"2025-03-22T19:51:14Z","timestamp":1742673074000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0145212625000372"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4]]},"references-count":28,"alternative-id":["S0145212625000372"],"URL":"https:\/\/doi.org\/10.1016\/j.leukres.2025.107677","relation":{},"ISSN":["0145-2126"],"issn-type":[{"value":"0145-2126","type":"print"}],"subject":[],"published":{"date-parts":[[2025,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Outcomes of triple-class refractory multiple myeloma patients at a single clinic: A retrospective study","name":"articletitle","label":"Article Title"},{"value":"Leukemia Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.leukres.2025.107677","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"107677"}}